Welcome to our September research update! Getting involved with research is an important way to impact food allergy treatments, education, and awareness.

This month, we are highlighting clinical trials, interviews, focus groups, and news on:

• FDA decision on neffy® epinephrine nasal spray
• New stock epinephrine and inhaler toolkits
• Intranasal powder epinephrine spray clinical results
• Eosinophilic gastroenteritis
  
  

Latest News on Food Allergies

AAFA Releases Statement on FDA Decision on neffy® Epinephrine Nasal Spray
On Sept. 19, the FDA rejected neffy, an epinephrine nasal spray to treat anaphylaxis, a severe allergic reaction. The FDA has asked for another study. The Asthma and Allergy Foundation of America (AAFA) released a statement about the FDA’s decision.

New Stock Epinephrine and Stock Inhaler Toolkits Improve Safety of Students with Anaphylaxis and Asthma
The American Academy of Allergy, Asthma & Immunology (AAAAI) has created new stock epinephrine and stock inhaler toolkits to help schools keep kids safe. The toolkits are designed to work in different states and schools to help prevent dangerous asthma and allergy emergencies and keep students safe. The epinephrine toolkit has information on what to do during a severe allergic reaction, training for non-medical staff, and videos to help students with allergies. The inhaler toolkit has resources on understanding state laws, how to help students having trouble breathing, and how to train staff.

Nestlé Divests Peanut Allergy Treatment Palforzia to Stallergenes Greer
Nestlé has sold its peanut allergy drug, Palforzia, to Stallergenes Greer, a Swiss biopharma company. Palforzia is an oral therapy that helps reduce peanut allergies by gradually exposing patients to small amounts of allergenic proteins. It was approved for children aged 4 to 17 and adults following a peanut-avoidant diet. This will expand Stallergenes Greer’s portfolio, which already has treatments for various allergies like grasses, mites, and trees.

Nasus Pharma Announces Publication of Positive Clinical Results for Its Epinephrine Intranasal Powder Spray
Nasus Pharma has shared positive findings from a study on their new epinephrine intranasal powder-based spray. This device, called FMXIN002, aims to provide quick and effective relief for severe allergic reactions caused by food, medicine, or insect bites. The study compared it to traditional epinephrine auto-injectors that deliver medicine through the muscle. The study found that FMXIN002 performed well, especially in simulating nasal congestion during allergic reactions. It delivered epinephrine quickly and effectively, with no significant side effects. This powder-based approach also offers better stability and longer shelf life compared to liquid forms of epinephrine. These results suggest that the new intranasal powder could be a promising and user-friendly solution for life-threatening allergies.